Tangential flow filtration is one of the most important separation techniques in biopharmaceutical manufacturing — used for concentrating, washing, and formulating biologics from antibodies to viral vectors. Here's how it works, and why the equipment matters as much as the membrane.
In conventional (dead-end) filtration, the feed solution pushes directly through a membrane. Retained material builds up on the surface until the membrane clogs. For large-scale bioprocessing, this is impractical — you'd need a new membrane every few minutes.
Tangential flow filtration (TFF) — also called crossflow filtration — solves this by flowing the feed solution parallel to the membrane surface, not directly through it. The crossflow continuously sweeps retained material away from the membrane, keeping it open and productive for hours or days.
A pressure differential across the membrane — called transmembrane pressure (TMP) — drives smaller molecules through as permeate. Larger molecules (your product) are retained in the retentate and recirculated back to the feed vessel. The process continues until the desired concentration or buffer composition is reached.
Key concept: The membrane decides what gets through based on size (molecular weight cut-off, or MWCO). The equipment — pump, valves, and sensors — determines how well the membrane can do its job without damaging your product.
TFF performs three core functions in downstream bioprocessing, often in sequence within a single run:
| Function | What happens | Typical use |
|---|---|---|
| Concentration (UF) | Solvent exits as permeate. Product stays in retentate. Volume drops, concentration rises. | Reducing batch volume after harvest or chromatography |
| Diafiltration (DF) | Fresh buffer added continuously while old buffer exits as permeate. Product stays, buffer exchanges. | Buffer exchange before formulation or between process steps |
| Formulation | Final UF/DF to reach target concentration and buffer composition for the drug substance. | Last step before fill-and-finish — preparing the product for its final form |
In a typical mAb downstream process, TFF appears twice: once after protein A chromatography to concentrate and buffer-exchange the eluate, and again at the end of purification to bring the drug substance to its final formulation conditions.
| Component | What it does | Why it matters |
|---|---|---|
| Pump | Drives feed solution across the membrane at the required crossflow rate | The pump contacts your product on every pass. Pump type determines shear force, pulsation amplitude, and cavitation risk — all of which affect product integrity |
| Membrane | Separates molecules by size (MWCO). Available in cassette and hollow fiber formats | MWCO selection determines what passes through. Format and surface chemistry affect fouling rate and recovery |
| Retentate pressure control valve | Adjusts back-pressure on the retentate line to control TMP | TMP stability determines flux consistency. A valve that can't hold position accurately creates TMP swings that push product into membrane pores and drive fouling |
| Pressure & flow sensors | Measure feed, retentate, and permeate pressures; crossflow rate; conductivity; UV absorbance | Real-time data enables closed-loop control of TMP and crossflow. Without accurate sensors, you're running blind |
| Feed vessel | Holds the retentate pool between pump passes | Vessel volume and geometry determine minimum working volume — directly affecting how much product you can recover at the end of the run |
As product is retained at the membrane surface, it forms a concentrated layer that restricts permeate flow — a phenomenon called concentration polarisation. Crossflow sweeps this layer away, but it's a dynamic balance: if TMP is too high relative to crossflow, polarisation builds faster than it's removed, flux declines, and the membrane can foul irreversibly.
The practical implication: there is an optimal operating window for every product and membrane combination. TMP and crossflow rate are the two control levers. The pump and retentate valve are the two pieces of hardware that determine whether you can hit and hold that window.
TFF is not always the right choice. For small volumes, low-viscosity feeds, or applications where membrane replacement is cheap and fast, dead-end filtration may be simpler and equally effective. The crossover point is typically determined by volume, fouling rate, and the value of the product being processed.
| Dead-End Filtration | TFF (Crossflow) | |
|---|---|---|
| Membrane lifetime per run | Single use until clogged | Hours to days — swept clean continuously |
| Suitable volume | Small to medium | Any scale — from 30 mL to thousands of liters |
| Concentration capability | Limited | High — product concentrated in retentate loop |
| Buffer exchange | Not practical | Yes — diafiltration mode |
| Equipment complexity | Low | Higher — pump, valves, sensors, control |
| Product exposure to pump | Single pass | Hundreds of passes — pump architecture matters |
The most common mistake in TFF: optimising the membrane while ignoring the equipment. The membrane decides what gets through. The pump, valve, and system design determine how much of what stays in survives the process intact.
Published data shows 20–40% yield loss during TFF for viral vectors. Where the loss actually comes from — and what to do about it.
The equipment variables that determine TFF yield — pump architecture, TMP stability, scale-up, and working volume.
Questions about TFF system selection for your process?
Speak to an engineer